Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Walleye Capital LLC

Walleye Capital LLC decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 12.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 427,230 shares of the company's stock after selling 61,223 shares during the period. Walleye Capital LLC owned about 0.55% of Travere Therapeutics worth $7,442,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Sterling Capital Management LLC grew its position in shares of Travere Therapeutics by 859.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock valued at $41,000 after purchasing an additional 2,115 shares during the period. R Squared Ltd acquired a new position in shares of Travere Therapeutics during the 4th quarter worth approximately $53,000. Summit Investment Advisors Inc. lifted its stake in Travere Therapeutics by 9.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock valued at $138,000 after acquiring an additional 667 shares during the last quarter. Victory Capital Management Inc. acquired a new position in Travere Therapeutics during the fourth quarter valued at approximately $182,000. Finally, Baader Bank Aktiengesellschaft bought a new stake in shares of Travere Therapeutics during the 4th quarter valued at approximately $192,000.

Insiders Place Their Bets

In related news, SVP William E. Rote sold 5,200 shares of the business's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $23.53, for a total value of $122,356.00. Following the sale, the senior vice president now directly owns 98,519 shares in the company, valued at approximately $2,318,152.07. The trade was a 5.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Sandra Calvin sold 3,348 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $67,361.76. Following the completion of the sale, the chief accounting officer now owns 63,654 shares of the company's stock, valued at $1,280,718.48. This trade represents a 5.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 188,877 shares of company stock worth $4,147,627. Company insiders own 3.75% of the company's stock.

Travere Therapeutics Stock Up 2.4 %

Travere Therapeutics stock traded up $0.35 during mid-day trading on Friday, reaching $14.92. The stock had a trading volume of 1,101,182 shares, compared to its average volume of 1,520,566. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -3.64 and a beta of 0.84. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $25.29. The company has a 50-day moving average price of $18.89 and a two-hundred day moving average price of $18.56.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.15). The business had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. On average, analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Travere Therapeutics in a report on Thursday, April 3rd. JPMorgan Chase & Co. lifted their price target on shares of Travere Therapeutics from $42.00 to $44.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. Citigroup increased their price objective on Travere Therapeutics from $31.00 to $35.00 and gave the company a "buy" rating in a report on Monday, February 24th. Guggenheim reaffirmed a "buy" rating and set a $47.00 target price on shares of Travere Therapeutics in a report on Monday. Finally, HC Wainwright increased their price target on Travere Therapeutics from $18.00 to $22.00 and gave the company a "buy" rating in a research note on Wednesday, January 15th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $32.08.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.